Resources from the same session
193MO - Development of a Deep Learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)
Presenter: Laura Vuduc
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
3MO - HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial
Presenter: Fara Brasó-Maristany
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
192MO - DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
Presenter: David Cameron
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Mini Oral session 2
Resources:
Webcast
125MO - Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
Presenter: Kenichi Inoue
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
126MO - HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
Presenter: Adrienne Waks
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 125MO and 126MO
Presenter: Carmen Criscitiello
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Mini Oral session 2
Resources:
Webcast
171MO - Inflammatory profiling of individuals with germline TP53 mutations (gTP53m) and its relationship to subsequent cancer development
Presenter: Tarek BEN AHMED
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
95MO - Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)
Presenter: Tanya Gupta
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast